Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis (BIOLUVE)

Grenoble Alpes University Hospital Center (CHU)

Status: Completed

Conditions: Subjects Clinically Suspected an Active Source of Toxoplasmosis Chorioretinitis Infection

Treatments: Other: Fluorescein angiography; Drug: Anti-toxoplasmosis treatment; Other: Puncture in anterior chamber; Drug: Anti-inflammatory treatments; Other: Dilated fundus examination; Biological: Toxoplasmosis serology

Study type: Interventional

Funder types: Other

Identifiers

NCT02843438

38RC09.014

Details and patient eligibility

About

Toxoplasmosis affects one to two newborn each 10000 births. Among them, 1 to 2 % develop learning disabilities or die, and 4 to 27 % develop a chorioretinitis sometimes leading to an amblyopia responsible for visual impairment. Toxoplasmosis uveitis affects too adults immunocompetent and immunodepressed who have had an acquired toxoplasmosis. Clinical diagnosis of ocular toxoplasmosis is more complicated in presence of posterior neuro-retinitis, inflammation of the papilla, uveitis without chorioretinitis, fuchs heterochromic iridocyclitis, scleritis, diffuse necrotizing or multifocal retinitis. In this situation biological markers diagnostic and prognostic of toxoplasmosis uveitis are useful.

Highly kept molecules (during evolution) like stress proteins (Hsp) are are found in the host and the pathogen and there can trigger a crossed immune response. Stress proteins haven't been explored yet, in the context of toxoplasmosis uveitis on humans.

The hypothesis is that Hsp70 and antibodies anti-Hsp70 are diagnostic and prognostic markers of ocular toxoplasmosis.

The goal is to evaluate diagnosis value of biological markers (Hsp70 and antibodies IgG anti-Hsp70) in toxoplasmosis uveitis.

Enrollment: 72 patients

Sex

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age over 18 years
• Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection
• Persons affiliated to national social security

Exclusion criteria

• Pregnant, parturient or breastfeeding women
• Persons deprived of liberty by judicial or administrative decision, person under legal protection
• Refusal by a patient to do the PCA (anterior chamber puncture)
• Patients whose following will be difficult or nonexistent

Trial design

Primary purpose: Screening

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

72 participants in 1 patient group

Subjects suspected of toxoplasmosis chorioretinitis infection

Other group

Description:

Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection

Treatment:

Other: Fluorescein angiography

Biological: Toxoplasmosis serology

Drug: Anti-toxoplasmosis treatment

Other: Dilated fundus examination

Other: Puncture in anterior chamber

Drug: Anti-inflammatory treatments